Analyst Ratings For Harvard Bioscience, Inc. (NASDAQ:HBIO)
Today, Janney Montgomery Scott reiterated its Buy rating on Harvard Bioscience, Inc. (NASDAQ:HBIO).
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Harvard Bioscience, Inc. (NASDAQ:HBIO) is Buy with a consensus target price of $11.00 per share, a potential 187.96% upside.
Some recent analyst ratings include
- 2/18/2019-Harvard Bioscience, Inc. (NASDAQ:HBIO) had its Buy rating reiterated by Janney Montgomery Scott
- 6/30/2018-Harvard Bioscience, Inc. (NASDAQ:HBIO) has coverage initiated with a Buy rating and $11.00 price target
- On 8/29/2018 James W. Green, Director, bought 2,500 with an average share price of $5.74 per share and the total transaction amounting to $14,350.00.
- On 8/29/2018 Robert E. Gagnon, CFO, sold 8,889 with an average share price of $5.77 per share and the total transaction amounting to $51,289.53.
- On 8/9/2018 Jeffrey Duchemin, CEO, sold 150,000 with an average share price of $6.18 per share and the total transaction amounting to $927,000.00.
- On 8/7/2018 Jeffrey Duchemin, CEO, sold 100,000 with an average share price of $6.07 per share and the total transaction amounting to $607,000.00.
- On 8/7/2018 Robert E Gagnon, CFO, sold 100,015 with an average share price of $6.08 per share and the total transaction amounting to $608,091.20.
- On 7/27/2018 Robert E. Gagnon, CFO, sold 62,514 with an average share price of $5.54 per share and the total transaction amounting to $346,327.56.
- On 7/23/2018 Robert E. Gagnon, CFO, sold 2,565 with an average share price of $5.25 per share and the total transaction amounting to $13,466.25.
About Harvard Bioscience, Inc. (NASDAQ:HBIO)
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Recent Trading Activity for Harvard Bioscience, Inc. (NASDAQ:HBIO)
Shares of Harvard Bioscience, Inc. closed the previous trading session at 3,82 +0,100 2,69 % with 3.72 shares trading hands.